Prostate Cell News Volume 2.20 | Jun 3 2011

The Ron Receptor Promotes Prostate Tumor Growth in the TRAMP Mouse Model
To examine the significance of Ron in prostate cancer in vivo, researchers utilized a genetically engineered mouse model that is predisposed to develop prostate tumors. [Oncogene]

Higher Doses of Radiation in Fewer Treatments Are Safe, Effective for Low-Risk Prostate Cancer
In a multicenter clinical trial, researchers have found that higher doses of stereotactic radiation therapy requiring fewer treatments are safe and effective for patients with low-to-intermediate-risk prostate cancer. [Press release from the University of Texas Southwestern Medical Center discussing online prepublication in the Journal of Clinical Oncology]

Benitec’s Gene Silencing Technology Used by Scientists in the Development of a Treatment for Radio-Resistant Prostate Cancer
Benitec Ltd. welcomed the publication of research by scientists who demonstrated the potential of Benitec’s gene silencing technology to provide effective human therapeutics for prostate cancer. [Press release from Benitec Ltd. discussing online prepublication in The Journal of Clinical Investigation]

Antifungal Drug Delays Need for Chemo in Advanced Prostate Cancer
The oral antifungal drug itraconazole may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease. [Press release from Johns Hopkins Medicine discussing research to be presented at the 2011 American Society of Clinical Oncology Annual Meeting]

Experimental Vaccine Made from Frozen Immune Cells Shows Promise for Prostate Cancer Patients
Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it, according to data. [Press release from ScienceDaily discussing research to be presented at the 2011 American Society of Clinical Oncology Annual Meeting]

LABORATORY RESEARCH

Prostate-Targeted Radiosensitization Via Aptamer-shRNA Chimeras in Human Tumor Xenografts
Scientists described the development of prostate-targeted RNAi agents that selectively sensitized prostate-specific membrane antigen–positive cells to ionizing radiation. [J Clin Invest]

EPLIN Downregulation Promotes Epithelial–Mesenchymal Transition in Prostate Cancer Cells and Correlates with Clinical Lymph Node Metastasis
By conducting quantitative proteomics in experimental models of human prostate cancer metastasis, investigators observed strikingly decreased expression of EPLIN (epithelial protein lost in neoplasm; or LIM domain and actin binding 1) upon epithelial–mesenchymal transition. [Oncogene]

FGFR-4 Arg388 Enhances Prostate Cancer Progression Via Extracellular Signal-Related Kinase and Serum Response Factor Signaling
Studies defined a signal transduction pathway downstream of FGFR-4 Arg388 (arginine at codon 388) that acts via extracellular signal-related kinase and serum response factor to promote prostate cancer progression. [Clin Cancer Res]

Androgens Repress Expression of the F-Box Protein Skp2 Via p107 Dependent and Independent Mechanisms in LNCaP Prostate Cancer Cells
Using the LNCaP prostate cancer cell line as a working model, the effect of androgens on the expression of Skp2 was examined by Western and Northern blot analyses. [Prostate]

Inhibition of N-Myc Downstream-Regulated Gene 2 in Prostatic Carcinoma
To study the expression of N-myc Downstream Regulated Gene-2 (NDRG2) in prostatic carcinoma (PCA) tissue and in different PCA cell lines, and to investigate its clinical and pathological implications, 144 PCA and benign prostatic hyperplasia tissue sections were analyzed retrospectively with immunohistochemistry. [Cancer Biol Ther]

Inhibitory Member of the Apoptosis-Stimulating Protein of p53 (ASPP) Family Promotes Growth and Tumorigenesis in Human p53-Deficient Prostate Cancer Cells
Investigators found that specially knocking down iASPP with lentivirus-mediated small interfering RNA inhibited the growth, in vitro colony-forming capacity and in vivo tumorigenesis of p53-defective prostate cancer cells. [Prostate Cancer Prostatic Dis]

CLINICAL RESEARCH

SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
Scientists hypothesized that genetic variants of androgen transporter genes, SLCO2B1 and SLCO1B3, may determine time to progression on androgen deprivation therapy. [J Clin Oncol]

Persistent, Biologically Meaningful Prostate Cancer After 1 Year of Androgen Ablation and Docetaxel Treatment
Researchers used a preoperative clinical discovery platform to prioritize pathways for assessment as therapeutic targets and to test the hypothesis that the primary site harbors potentially lethal tumors after aggressive treatment. [J Clin Oncol]

Phase I Dose-Escalation Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer
The purpose of this study was to evaluate the tolerability of escalating doses of stereotactic body radiation therapy in the treatment of localized prostate cancer. [J Clin Oncol]

ICR Scientist to Receive Inaugural Wellcome Trust Investigator Award
Professor Dale Wigley of The Institute of Cancer Research (ICR) has been announced as a recipient of one of the inaugural Wellcome Trust Investigator Awards. [The Institute of Cancer Research Press Release]

Prostate Cancer Drug Developers Win Royal Society of Chemistry Award
A team of scientists at The Institute of Cancer Research has won a prestigious Royal Society of Chemistry award for the discovery and clinical development of prostate cancer drug abiraterone. [The Institute of Cancer Research Press Release]

Flotte Elected to ASGCT Advisory Council
Terence R. Flotte, M.D., has been elected to a five-year term on the Advisory Council of the American Society of Gene & Cell Therapy (ASGCT). [University of Massachusetts Medical School Press Release]

UCSF School of Medicine Names Vice Dean of Education
Catherine Reinis Lucey, M.D., has been appointed vice dean for education in the University of California, San Francisco (UCSF) School of Medicine, effective September 1. [University of California, San Francisco Press Release]

NEW American Association for Cancer Research International Conference New Horizons in Cancer Research: Biology to Prevention to Therapy
December 13-16, 2011
Gurgaon, India

Visit our events page to see a complete list of events in the prostate cell community.

Chemist (STEMCELL Technologies)

Lab Technologist – Cell Separation (STEMCELL Technologies)

Research and Development Senior Technologist (STEMCELL Technologies)

Post-doctoral Position – Molecular Biology of Prostate Cancer (Baylor College of Medicine)

Postdoctoral Position – Endocrinology of Prostate Cancer (Baylor College of Medicine)

Assistant/Associate Research Scientist (New York University)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.